Vifor Pharma Ag Stock Cash And Equivalents
| GNHAYDelisted Stock | USD 38.39 0.00 0.00% |
Vifor Pharma AG fundamentals help investors to digest information that contributes to Vifor Pharma's financial success or failures. It also enables traders to predict the movement of Vifor Pink Sheet. The fundamental analysis module provides a way to measure Vifor Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vifor Pharma pink sheet.
Vifor |
Vifor Pharma AG Company Cash And Equivalents Analysis
Vifor Pharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Vifor Pharma Cash And Equivalents | 993.6 M |
Most of Vifor Pharma's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vifor Pharma AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Vifor Pharma AG has 993.6 M in Cash And Equivalents. This is 21.04% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all United States stocks is 63.23% higher than that of the company.
Vifor Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vifor Pharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Vifor Pharma could also be used in its relative valuation, which is a method of valuing Vifor Pharma by comparing valuation metrics of similar companies.Vifor Pharma is currently under evaluation in cash and equivalents category among its peers.
Vifor Fundamentals
| Return On Equity | 0.0665 | |||
| Return On Asset | 0.0458 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 10.99 B | |||
| Shares Outstanding | 324.46 M | |||
| Price To Earning | 30.39 X | |||
| Price To Book | 3.22 X | |||
| Price To Sales | 6.39 X | |||
| Revenue | 1.82 B | |||
| Gross Profit | 1.14 B | |||
| EBITDA | 519.6 M | |||
| Net Income | 144.4 M | |||
| Cash And Equivalents | 993.6 M | |||
| Cash Per Share | 3.06 X | |||
| Total Debt | 75 M | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 1.91 X | |||
| Book Value Per Share | 10.76 X | |||
| Cash Flow From Operations | 527.4 M | |||
| Earnings Per Share | 0.49 X | |||
| Number Of Employees | 2.2 K | |||
| Beta | 1.03 | |||
| Market Capitalization | 12.45 B | |||
| Total Asset | 5.1 B | |||
| Retained Earnings | 2.01 B | |||
| Working Capital | 567 M | |||
| Current Asset | 1.29 B | |||
| Current Liabilities | 726 M | |||
| Z Score | 99.6 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 5.1 B | |||
| Last Dividend Paid | 2.0 |
About Vifor Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vifor Pharma AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vifor Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vifor Pharma AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |